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Cytomegalovirus (CMV) infection remains one of the most important complications of allogeneic stem cell transplantations (SCT) although the impact on morbidity and mortality has been reduced during the last decade by improvements to management. Several different advances have been made. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) has therefore produced recommendations reflecting recent changes. The recommendations are graded according to the United States Center for Disease Control (CDC) as described in Table 1 .
Pretransplant management and donor selection
Patients who are uninfected with Cytomegalovirus (CMV), that is seronegative, have a low risk for contracting CMV infection with proper management. [1] [2] [3] It is therefore important to assess CMV serological status as early as possible when a candidate is considered for allogeneic stem cell transplantation (SCT).
If a patient is found to be seronegative, a CMV seronegative donor should be used if possible (AI). All products given before transplantation should either be leukocyte depleted or come from CMV seronegative blood donors (AI).
Other prophylactic methods such as antiviral prophylaxis or immune globulin have no role during this phase (DII).
If the patient is found to be seropositive, the choice of the proper donor is controversial. In a recent study from the European Group for Blood and Marrow Transplantation (EBMT), seropositive patients undergoing unrelated, non-T-cell-depleted SCT had an improved survival if they received a graft from a seropositive donor. 4 However, another study from the NMDP failed to find such a protective effect. 5 No protective effect of donor serological status was found if the donor was an human leukocyteantigen (HLA)-identical sibling.
Diagnosis of CMV infection
During the last 15 years, several techniques have been developed that allow the increasingly rapid and sensitive diagnosis of CMV. The currently used tests are based on the detection of antigen, DNA, or mRNA.
For the diagnosis of CMV infection, it has been convincingly shown that the detection of CMV from blood has a strong prognostic impact on subsequent development of CMV disease. 6 This is the basis for the so-called preemptive therapy management strategy (see below). A few studies have reported that screening by broncho-alveolar lavage (BAL) is predictive for the development of CMV pneumonia. 7 However, since blood monitoring is easier and allows quantitation of the viral load, use of BAL monitoring is not recommended. Serologic determination of either IgG or IgM has no place in the diagnosis of CMV infection or disease in SCT recipients.
The tests that have been most thoroughly evaluated for the detection of CMV in peripheral blood are the antigenaemia test (detecting pp65) 8, 9 and polymerase chain reaction (PCR) for CMV DNA. [10] [11] [12] [13] Other techniques for detecting DNA such as the hybrid capture assay have also been introduced. 14 The specimen used for PCR varies between different laboratories and whole blood, or peripheral blood leukocytes, or plasma can be used. The previously used shell vial (rapid culture or DEAFF test) is today regarded as too insensitive for monitoring at least high-risk allogeneic SCT patients. 10 More recently, the quantitation of viral load by PCR has been recognized as giving important prognostic information and the introduction of so-called Real Time or Light Cycler technologies has made this technology widely available. 11, [15] [16] [17] [18] Since these tests vary from laboratory to laboratory, each centre should establish a good collaboration with the diagnostic laboratory to determine how tests results should be interpreted in their clinical practice. Detection of mRNA by nucleic acid sequence-based amplification (NASBA) is also a sensitive and rapid technique and has, in randomised trials, been shown to be similarly effective as pp65 antigenaemia or detection of DNA by PCR. 19, 20 Only a few studies have been performed in autologous SCT patients, but the limited data suggest that antigenemia can predict the development of CMV disease. 21, 22 Due to the overall low frequency of CMV disease in most autologous SCT patient populations even without preemptive antiviral therapy or antiviral prophylaxis, the cost-effectiveness of routine monitoring is likely to be unfavourable. However, it is recognised that there are subgroups of such patients at higher risk for CMV disease such as those patients who received CD34-selected grafts and those who have had prior treatment with fludarabine or 2-CDA. 21 The potential benefit of monitoring and intervention in autologous stem cell transplant patients perceived to have an increased risk of CMV disease is unknown.
It has been well recognised that patients lacking a specific immune response to CMV are at a much increased risk for developing CMV disease. [23] [24] [25] [26] [27] Therefore it would be logical to monitor the development of a CMV-specific immune response. There are several techniques available assessing either the T-helper or the T-cytotoxic response. [28] [29] [30] [31] However, none are standardised for routine use.
It is recommended that all allogeneic SCT patients, regardless of whether or not they receive CMV prophylaxis, be monitored for CMV in peripheral blood at least weekly with either the CMV antigenaemia assay or a technique for the detection of either CMV DNA or RNA (AI). The duration of monitoring should be at least 100 days (AI). Longer monitoring is recommended in patients with acute or chronic graft-versus-host disease (GVHD), those who experienced an earlier CMV reactivation, and those who underwent mismatched or unrelated donor transplantation (BII).
It is not recommended that autologous SCT patients be routinely monitored for CMV. However, certain highrisk patients might potentially benefit from monitoring and the use of pre-emptive therapy (BII).
Diagnosis of CMV disease
Diagnosis of CMV disease must be based on symptoms consistent with CMV disease together with the detection of CMV in the appropriate specimen from the involved tissue. Symptoms of organ involvement together with CMV detection in blood are not enough for the diagnosis of CMV disease. There are several possible techniques that can be used for the detection of CMV in tissue specimens and each transplant centre should collaborate closely with a good diagnostic virology and histopathological laboratory. More detailed definitions of CMV disease have been published elsewhere. 32 
Prevention of CMV disease
The different preventive strategies for CMV disease include use of the appropriate blood products, immune globulin, and use of antiviral agents either as chemoprophylaxis or pre-emptive therapy. The currently available antiviral agents for the prevention of CMV infection and disease are acyclovir, valacyclovir, ganciclovir, valganciclovir, foscarnet, and cidofovir.
Blood products and immune globulin
In a seronegative patient with a seronegative donor, the risk for CMV infection is mainly through blood products. There are two ways of reducing the risk of CMV transmission from blood products: use of leukocytedepleted blood products or blood products from CMV seronegative donors. 1, 2 There is no clear advantage for one over the other, 1,3 although a recent retrospective study suggests a lower risk of breakthrough CMV infection with Table 1 Evidence-based system used to determine strength of recommendations 33 Immune globulin is not useful as primary CMV prophylaxis. 34 There is a clear indication to give leukocytedepleted blood products or blood products from CMV seronegative donors to CMV seronegative allogeneic stem cell transplant patients. 2 Although the benefit is less clear in autologous SCT recipients, CMV disease after primary infection does occur and then the mortality is high also in autologous transplantation recipients.
No study of CMV seronegative or leukocyte-depleted blood products has been performed in CMV seronegative patients with CMV seropositive donors. However, since the risk for transmission from blood products must be taken into account, it makes sense to use low-risk blood products also in this subgroup. Two studies with immune globulin have been performed in this subgroup and it was shown that immune globulin prophylaxis is not effective. 34, 35 In seropositive patients regardless of donor status, there are no data supporting the use of leukocyte-depleted or CMV seronegative blood products, although superinfections with new CMV strains can occur. However, it might be useful to have the same procedure in place for all stem cell transplant patients to avoid administration of the incorrect type of blood products to seronegative patients. Several studies regarding immune globulin prophylaxis were performed and a meta-analysis has shown a modest effect in reducing the risk for CMV disease. 36 However, these studies were performed mostly more than a decade ago without other types of preventive strategies available (see below).
CMV seronegative allogeneic stem cell transplant patients with CMV seronegative donors (AI) and CMV seronegative autologous stem cell transplant patients should receive leukocyte-depleted or CMV seronegative blood products only (BII). Immune globulin for the prevention of CMV infection or disease is not recommended (DII).
Antiviral chemoprophylaxis
Antiviral chemoprophylaxis could be used for all patients or subgroups of patients, that is patients at perceived high risk for CMV disease. Several different drugs can be used for this indication. Dosages for antiviral drugs in SCT recipients are given in Table 2 .
In randomised studies both acyclovir and valacyclovir were shown to reduce the risk of CMV infection, but not CMV disease. 37, 38 One study also reported improved survival, although the mechanism for this improvement has not been elucidated. 37 Valacyclovir prophylaxis can reduce the need for pre-emptive therapy, but monitoring for CMV and use of pre-emptive therapy is absolutely essential if acyclovir/valacyclovir prophylaxis is to be used. 38 Intravenous ganciclovir prophylaxis has been tested in four randomised trials. Two studies compared ganciclovir to placebo, 39, 40 one study compared prophylactic to preemptive ganciclovir, 9 and one study compared ganciclovir to valacyclovir. 41 Ganciclovir prophylaxis reduced the risk of CMV disease compared to placebo, but did not improve survival. There was no difference in the risk of CMV disease or the chance of survival between ganciclovir and valacyclovir prophylaxis, or between ganciclovir prophylaxis and ganciclovir given as pre-emptive therapy. Ganciclovir prophylaxis has been associated with the risk of delayed CMV-specific immune reconstitution and the development of late CMV disease. 42 However, it should be noted that a recent study showed no difference in immune reconstitution to CMV between patients receiving prophylactic and pre-emptive ganciclovir, and that subclinical CMV reactivation during ganciclovir therapy was a potent stimulator of the specific immune response. 24 Oral ganciclovir has not been studied in controlled trials, and poor gastrointestinal absorption limits its usefulness. Valganciclovir is the prodrug of ganciclovir and has better bioavailability. Several studies are ongoing to assess its efficacy as prophylaxis. Foscarnet prophylaxis has only been used in uncontrolled trials.
Acyclovir or valacyclovir can be used as prophylaxis against CMV in allogeneic SCT patients. However, their use must be combined with monitoring and use of preemptive therapy (A1). Intravenous ganciclovir prophylaxis is an effective strategy for the prevention of CMV disease and could be used in subgroups of allogeneic SCT patients perceived to have a high risk for CMV disease (A1). The doses given here are guidelines only. Please refer to your local pharmacist for confirmation of details. Given dosages must be adjusted for renal function.
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Further studies are needed to assess the usefulness of valganciclovir given as prophylaxis (CIII).
Pre-emptive antiviral therapy
The strategy of pre-emptive antiviral therapy is defined as patients receiving anti-CMV therapy when they have evidence of active, but asymptomatic, CMV infection. This strategy is today the first-line alternative instead of general prophylaxis for CMV management at many centres both in Europe and in the US. 43, 44 Pre-emptive antiviral therapy should be based on CMV detection in blood either by the antigenaemia test or by a test detecting CMV nucleic acid, and has been widely used during the last decade. It has been shown both in randomized controlled trials and in uncontrolled patient series to be effective for reduction of the risk of CMV disease and to reduce CMV-associated mortality. 10 One advantage of pre-emptive therapy over ganciclovir prophylaxis is that a lower proportion of patients will need antiviral therapy since not all patients at risk for CMV will develop active infection. Recent studies indicate that additional information regarding the risk for development of CMV disease can be obtained by determination of the viral load (for example, by quantitative PCR), and although it is not possible to give definite rules at the moment, it is clear that the risk of CMV disease is significantly increased with each log 10 rise in CMV load. 11, 45 Furthermore, the speed of viral replication shown as the rate of viral load increase in subsequent samples is also prognostic for the development of CMV disease.
No controlled study of pre-emptive therapy has been performed in autologous SCT recipients but uncontrolled trials have not supported its routine use.
A randomised trial has shown that intravenous ganciclovir or foscarnet are both equally effective as pre-emptive therapy. 46 The possibility that intravenous ganciclovir can be replaced by valganciclovir is currently being investigated in clinical trials. Cidofovir has been studied only in uncontrolled trials, and although the weekly dosing regimen is attractive, the toxicity profile is such that this agent should be used as a second-line drug for pre-emptive therapy. 47 The combination of intravenous ganciclovir and foscarnet given simultaneously has also been in a recently performed randomised trial using half dosages of both agents, but no result is currently available.
The duration of therapy is a minimum of 2 weeks, depending on whether CMV is detected or not at the end of the 2-week course. A rise in viral load during the first week of antiviral therapy, either assessed by antigenaemia or quantitative PCR, is not an indication of therapy failure and there is no need to change the drug. 48 If CMV is still detected after 2 weeks of therapy, maintenance therapy can be given. 46 Repeated courses of pre-emptive therapy or a prolonged duration of initial pre-emptive therapy might be needed in particular in patients who have undergone an unrelated or mismatched transplantation.
Pre-emptive antiviral therapy based on the detection of CMV antigen or nucleic acid is the recommended preventive strategy for allogeneic SCT patients (AI).
Ganciclovir prophylaxis is another possibility in highrisk patients (AI). Either intravenous ganciclovir or foscarnet can be used for first-line pre-emptive therapy. The choice depends on the risk of toxicity and which antiviral drugs have been used previously (Table 3 ; AI). Cidofovir can be considered for second-line pre-emptive therapy (BII).
CMV disease
CMV disease, in particular CMV pneumonia, is still today associated with a high mortality. 23, 49 Therefore, development of CMV disease should be regarded as a failure of the preventive strategy. CMV disease can develop any time after SCT from the early neutropenic phase up to several years after transplantation, and currently at least 50% of CMV disease develops later than 100 days after transplantation. 23 CMV retinitis is more common as a late rather than an early manifestation of CMV disease, and patients developing visual disturbances should be assessed by an ophthalmologist.
50,51 CMV disease is rare in autologous stem cell transplant patients but is associated with a similar morbidity and mortality as that after allogeneic SCT. 21, 52 No controlled study has been performed for the treatment of CMV disease. The established therapy for CMV pneumonia is a combination of intravenous ganciclovir and high-dose intravenous immune globulin. [53] [54] [55] [56] Whether the addition of immune globulin adds efficacy is still controversial and a recent uncontrolled study questions the practice. 49 No data support that there is any advantage of so-called CMV hyperimmune globulin over standard immune globulin. There are no data to support adding immune globulin for the treatment of any other manifestation of CMV disease than pneumonia. 57 There is no standard therapy duration for CMV disease, but a commonly used schedule is 21-28 days of induction therapy followed by maintenance therapy for 4 weeks. Either cidofovir or the combination of intravenous ganciclovir and foscarnet, each given in full dosage, may be used as second-line therapy for CMV disease.
Despite the lack of controlled data, the combination of intravenous ganciclovir and immune globulin is recommended for the therapy of CMV pneumonia (BII). For other types of CMV disease, either intravenous ganciclovir or foscarnet given without the addition of immune globulin is recommended (BII). Cidofovir or the combination of intravenous ganciclovir and foscarnet can be used as second-line therapy of CMV disease (BII).
Resistance
Resistance to antiviral drugs has been common in AIDS patients but is more rarely encountered in SCT patients. 48, 58 Resistance usually does not emerge until after several weeks of antiviral therapy. It should be recognized that there is a difference between clinical resistance and viral resistance. Clinical resistance depends on host factors, while viral resistance is due to mutations in the viral genome. In most situations where CMV can still be detected despite adequate antiviral therapy, the cause is clinical rather than viral resistance. The presence of antiviral resistance can be determined by either phenotypic or genotypic assays. The development of DNA sequencing technology allows for screening of the most commonly seen mutations in ganciclovir-resistant strains of CMV. Testing for foscarnet, cidofovir and the less common ganciclovir-resistant mutants is, however, more difficult as the mutations are less well defined. Development of double and triple resistant strains is very rare, but does occur.
Rising CMV antigenaemia or DNA levels, or progress of CMV disease symptoms might indicate clinical or viral resistance. There is no controlled study addressing the question about changing antiviral therapy from, for example, ganciclovir to foscarnet based on results of CMV monitoring. It has been shown that a rise in the viral load during the first week of such treatment is not an indication of viral resistance. 48 Although not based on data, our opinion is that most patients do not benefit from a change of antiviral therapy based on laboratory markers (rising antigenaemia or DNA levels) in the absence of clinical symptoms during the first 2 weeks of antiviral therapy. The situation is more difficult in patients with progression of clinical symptoms of CMV disease. Patients with CMV pneumonia that progress on therapy are frequently in a desperate situation, and an addition of foscarnet to ganciclovir (or vice versa) or a switch to cidofovir could be considered
Where possible, resistance testing should be performed to allow selection of the correct second-line antiviral therapy (BIII). If turn-around time for resistance testing is prolonged, then a change of treatment for a patient with rising viral load or worsening disease in the face of adequate treatment could precede receipt of the test result (BII).
Adoptive immunoprophylaxis
During recent years several groups have studied the usefulness of adoptive, specific immunoprophylaxis through the transfer of T-cells. 29, 59 This technology does not seem to be associated with significant toxicity, but its effectiveness needs to be assessed in controlled trials. It is currently to be regarded as experimental.
